Truist initiates Altimmune stock coverage with buy rating on drug potential

📌 Key Takeaways

• Truist initiated coverage on Altimmune stock with a buy rating.
• The rating is based on the potential of Altimmune's drug pipeline.
• This suggests analyst confidence in the company's future performance.
• The move may influence investor interest in Altimmune.

🏷️ Themes

Pharmaceuticals, Stock Analysis

Entity Intersection Graph

No entity connections available yet for this article.

Source

investing.com